comparemela.com

Latest Breaking News On - Single event study - Page 1 : comparemela.com

Pulmatrix (PULM) Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine

Pulmatrix (PULM) Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Margaret-wasilewski
Ted-raad
Drug-administration
Pulmatrix-inc
Single-event-study
Dihydroergotamine-mesylate-inhalation-powder
Acute-treatment
Chief-medical-officer
Chief-executive-officer

Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine

/PRNewswire/ Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled.

United-states
American
Margaret-wasilewski
Timothy-mccarthy
Ted-raad
Drug-administration
Company-quarterly-reports-on-form
Prnewswire-pulmatrix-inc
Exchange-commission
Pulmatrix-inc
Single-event-study
Dihydroergotamine-mesylate-inhalation-powder

vimarsana © 2020. All Rights Reserved.